FDA Works To Fill Advisory Panel Seats While Tightening Conflict Rules
This article was originally published in The Tan Sheet
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats
You may also be interested in...
The possible release of FDA's voluminous documents is one of the more challenging aspects - both in policies and resources - of the agency's effort to make its operations and decisions more open to the public, FDA's Janet Woodcock says
Provisions of the health care reform law may lead to greater acceptance of dietary supplements in promoting wellness and prevention and reducing health care costs
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says